SCLX Market Analysis

Overview

Fundamentals

P/E ratioForward 2.66
EPS (TTM)$-36.480.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$74.4MMicro cap

Valuation

Forward P/E
2.66
PEG ratio
P/B
28.85
P/S (TTM)
2.46
EV/EBITDA
-2.64

Profitability & growth

ROE (TTM)
0.0%
Operating margin
-782.0%
Revenue growth YoY
-67.8%
Dividend yield
Beta
1.42
Last earnings
Feb 25, 2026 · Estimate $-0.47 · Reported $-1.17
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Scilex Holding Company

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company is headquartered in Palo Alto, California.

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
960 SAN ANTONIO ROAD, PALO ALTO, CA
Fiscal year end
December
Latest quarter
Mar 31, 2026
Market cap$74.4M
Shares outstanding$7.0M
52W high$34.27
52W low$3.92

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer